Does the media refer more to BEAM or CRSP?

In the previous week, Beam Therapeutics had 2 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 12 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.63 beat Beam Therapeutics' score of 0.50 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNLI or BEAM?

In the previous week, Beam Therapeutics had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 11 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.78 beat Beam Therapeutics' score of 0.50 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to EDIT or BEAM?

In the previous week, Beam Therapeutics had 12 more articles in the media than Editas Medicine. MarketBeat recorded 14 mentions for Beam Therapeutics and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.94 beat Beam Therapeutics' score of 0.50 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BEAM or NTLA?

In the previous week, Beam Therapeutics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 13 mentions for Intellia Therapeutics. Beam Therapeutics' average media sentiment score of 0.50 beat Intellia Therapeutics' score of 0.44 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BEAM or PRME?

In the previous week, Beam Therapeutics had 6 more articles in the media than Prime Medicine. MarketBeat recorded 14 mentions for Beam Therapeutics and 8 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.85 beat Beam Therapeutics' score of 0.50 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Beam Therapeutics (BEAM) Competitors

$31.00 -1.68 (-5.14%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$31.08 +0.08 (+0.26%)

As of 04:17 AM Eastern

Compare

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

Should you buy Beam Therapeutics stock or one of its competitors? MarketBeat compares Beam Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Beam Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry.

How does Beam Therapeutics compare to CRISPR Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Beam Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

Beam Therapeutics has a net margin of -39.66% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.82	-$79.99M	-$0.68	N/A
CRISPR Therapeutics	$3.51M	1,391.24	-$581.60M	-$6.22	N/A

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Beam Therapeutics had 2 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 12 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.63 beat Beam Therapeutics' score of 0.50 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics currently has a consensus price target of $46.85, suggesting a potential upside of 51.12%. CRISPR Therapeutics has a consensus price target of $67.78, suggesting a potential upside of 33.87%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Beam Therapeutics beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Beam Therapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Denali Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Denali Therapeutics presently has a consensus price target of $34.75, indicating a potential upside of 31.23%. Beam Therapeutics has a consensus price target of $46.85, indicating a potential upside of 51.12%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Beam Therapeutics had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 11 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.78 beat Beam Therapeutics' score of 0.50 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	12.71	-$512.54M	-$2.88	N/A
Beam Therapeutics	$139.74M	22.82	-$79.99M	-$0.68	N/A

Summary

Beam Therapeutics beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	7.64	-$160.06M	-$1.23	N/A
Beam Therapeutics	$139.74M	22.82	-$79.99M	-$0.68	N/A

Editas Medicine presently has a consensus target price of $5.40, indicating a potential upside of 70.89%. Beam Therapeutics has a consensus target price of $46.85, indicating a potential upside of 51.12%. Given Editas Medicine's higher possible upside, equities research analysts plainly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Beam Therapeutics has a net margin of -39.66% compared to Editas Medicine's net margin of -281.59%. Beam Therapeutics' return on equity of -29.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

In the previous week, Beam Therapeutics had 12 more articles in the media than Editas Medicine. MarketBeat recorded 14 mentions for Beam Therapeutics and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.94 beat Beam Therapeutics' score of 0.50 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Editas Medicine has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market.

Summary

Beam Therapeutics beats Editas Medicine on 14 of the 17 factors compared between the two stocks.

How does Beam Therapeutics compare to Intellia Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.82	-$79.99M	-$0.68	N/A
Intellia Therapeutics	$67.67M	26.88	-$412.69M	-$3.54	N/A

Beam Therapeutics presently has a consensus target price of $46.85, indicating a potential upside of 51.12%. Intellia Therapeutics has a consensus target price of $20.67, indicating a potential upside of 58.79%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Beam Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Beam Therapeutics has a net margin of -39.66% compared to Intellia Therapeutics' net margin of -597.04%. Beam Therapeutics' return on equity of -29.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

In the previous week, Beam Therapeutics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 13 mentions for Intellia Therapeutics. Beam Therapeutics' average media sentiment score of 0.50 beat Intellia Therapeutics' score of 0.44 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Beam Therapeutics beats Intellia Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Prime Medicine?

Beam Therapeutics (NASDAQ:BEAM) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Beam Therapeutics currently has a consensus price target of $46.85, suggesting a potential upside of 51.12%. Prime Medicine has a consensus price target of $7.53, suggesting a potential upside of 114.57%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Beam Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.26, meaning that its stock price is 126% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.82	-$79.99M	-$0.68	N/A
Prime Medicine	$4.63M	136.93	-$201.14M	-$1.23	N/A

Beam Therapeutics has a net margin of -39.66% compared to Prime Medicine's net margin of -4,917.55%. Beam Therapeutics' return on equity of -29.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

In the previous week, Beam Therapeutics had 6 more articles in the media than Prime Medicine. MarketBeat recorded 14 mentions for Beam Therapeutics and 8 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.85 beat Beam Therapeutics' score of 0.50 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Prime Medicine on 9 of the 16 factors compared between the two stocks.

Get Beam Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAM vs. The Competition

Export

Metric	Beam Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.36B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-45.59	20.85	27.11	24.26
Price / Sales	22.82	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	2.54	8.49	10.75	6.29
Net Income	-$79.99M	$23.83M	$3.58B	$330.66M
7 Day Performance	-18.25%	-3.56%	-2.06%	-1.32%
1 Month Performance	6.79%	6.31%	3.32%	-0.64%
1 Year Performance	46.43%	48.30%	26.36%	19.08%

Beam Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAM Beam Therapeutics	3.3734 of 5 stars	$31.00 -5.1%	$46.85 +51.1%	+46.5%	$3.36B	$139.74M	N/A	510	Gap Down
CRSP CRISPR Therapeutics	3.3992 of 5 stars	$61.89 +3.0%	$67.78 +9.5%	-10.9%	$5.79B	$3.51M	N/A	460
DNLI Denali Therapeutics	3.2886 of 5 stars	$25.74 -0.3%	$34.25 +33.1%	+82.4%	$4.10B	$330.53M	N/A	430	News Coverage Analyst Forecast
EDIT Editas Medicine	2.5469 of 5 stars	$3.65 flat	$5.40 +47.9%	+9.7%	$357.36M	$40.52M	N/A	230	Gap Down
NTLA Intellia Therapeutics	3.2428 of 5 stars	$17.84 +1.6%	$20.46 +14.7%	+12.9%	$2.45B	$67.67M	N/A	600	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAM) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beam Therapeutics (BEAM) Competitors

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

How does Beam Therapeutics compare to CRISPR Therapeutics?

Summary

How does Beam Therapeutics compare to Denali Therapeutics?

Summary

How does Beam Therapeutics compare to Editas Medicine?

Summary

How does Beam Therapeutics compare to Intellia Therapeutics?

Summary

How does Beam Therapeutics compare to Prime Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM vs. The Competition

Beam Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beam Therapeutics (BEAM) Competitors

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

How does Beam Therapeutics compare to CRISPR Therapeutics?

Which has more risk and volatility, BEAM or CRSP?

Is BEAM or CRSP more profitable?

Which has better earnings and valuation, BEAM or CRSP?

Do insiders & institutionals hold more shares of BEAM or CRSP?

Does the media refer more to BEAM or CRSP?

Do analysts recommend BEAM or CRSP?

Summary

How does Beam Therapeutics compare to Denali Therapeutics?

Which has more volatility and risk, DNLI or BEAM?

Is DNLI or BEAM more profitable?

Do insiders and institutionals believe in DNLI or BEAM?

Do analysts prefer DNLI or BEAM?

Does the media refer more to DNLI or BEAM?

Which has better earnings & valuation, DNLI or BEAM?

Summary

How does Beam Therapeutics compare to Editas Medicine?

Which has stronger valuation & earnings, EDIT or BEAM?

Do analysts recommend EDIT or BEAM?

Is EDIT or BEAM more profitable?

Does the media refer more to EDIT or BEAM?

Do institutionals & insiders believe in EDIT or BEAM?

Which has more risk and volatility, EDIT or BEAM?

Summary

How does Beam Therapeutics compare to Intellia Therapeutics?

Which has better valuation and earnings, BEAM or NTLA?

Do analysts prefer BEAM or NTLA?

Which has more risk & volatility, BEAM or NTLA?

Do insiders and institutionals believe in BEAM or NTLA?

Is BEAM or NTLA more profitable?

Does the media prefer BEAM or NTLA?

Summary

How does Beam Therapeutics compare to Prime Medicine?

Do analysts prefer BEAM or PRME?

Do institutionals and insiders hold more shares of BEAM or PRME?

Which has more risk and volatility, BEAM or PRME?

Which has preferable earnings and valuation, BEAM or PRME?

Is BEAM or PRME more profitable?

Does the media favor BEAM or PRME?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM vs. The Competition

Beam Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools